Hemophilia A Management

Introduction

• Hemophilia A is characterized by a deficiency of functional coagulation factor VIII (FVIII), which is encoded by the F8 gene and primarily produced by liver sinusoidal endothelial cells, with the F8 gene located on the X chromosome 1, 2
• Hemophilia A is more common than Hemophilia B, accounting for approximately 80-85% of all hemophilia cases, affecting 24.6 per 100,000 males at birth 2
• Patients with Hemophilia A experience spontaneous and trauma-induced recurrent bleeding, especially in joints and muscles in severe cases, and are at risk of potential life-threatening bleeding in the brain and other internal organs 1

Classification and Diagnosis

• Hemophilia A severity is classified based on plasma levels of factor VIII (FVIII) activity as follows: Severe (<1% factor VIII activity), Moderate (1-5% factor VIII activity), and Mild (>5-40% factor VIII activity), as defined by the International Society on Thrombosis and Haemostasis (ISTH) 3, 4, 2
• The classification system is based on factor VIII levels, but it's essential to recognize that there can be clinical heterogeneity in bleeding patterns among patients with the same factor VIII levels 3
• The following table summarizes the standard classification of Hemophilia A severity:

2

Treatment Approaches

• The World Health Organization recommends factor VIII replacement therapy as the primary treatment for patients with low Factor VIII activity, with treatment approach determined by disease severity, presence of inhibitors, and bleeding status, and according to the Haematologica journal, administration can be done through bolus or continuous infusion, with dosing of 20-50 IU/kg every 6-8 hours or 3-4 IU/kg/hour, respectively 4
• For patients with mild hemophilia A, desmopressin (DDAVP) can be used as an alternative, with dosing of 0.3 μg/kg intravenously, administered 30 minutes prior to procedures, and is best for minor bleeding episodes, but may cause water retention, hyponatremia, and convulsions with repeated use, as stated by the Haematologica journal 4
• The World Federation of Hemophilia strongly recommends prophylactic therapy over episodic treatment for severe hemophilia A to prevent joint damage and improve quality of life, with standard prophylaxis involving regular FVIII infusions (at least once per week) 4
• Prophylactic therapy with FVIII concentrates is strongly recommended over episodic treatment for severe hemophilia A, which accounts for 80-85% of all hemophilia cases 2
• Gene therapy using recombinant adeno-associated virus (AAV) vectors to transfer functional F8 genetic information into hepatocytes is a treatment option for Hemophilia A, as recommended by the American Society of Hematology 1
• Emicizumab, a subcutaneously administered FVIII-mimetic bispecific monoclonal antibody, is approved for Hemophilia A prophylaxis and is preferred over bypassing agents for patients with inhibitors 1, 2

Bypassing Agents

• Recombinant activated Factor VII (rFVIIa) can be used as a bypassing agent, with dosing of 90 μg/kg every 2-3 hours until hemostasis, and alternative regimens of 46-150 mcg/kg every 2-24h or continuous infusions (8-50 mg/kg/h), with efficacy of 90% in non-surgical cases, as reported by the Haematologica journal, with a strength of evidence not explicitly stated but implied to be high due to the efficacy rate 4
• Activated Prothrombin Complex Concentrates (aPCCs) can also be used, with dosing of 50-100 IU/kg every 8-12 hours (maximum 200 IU/kg/day), although the strength of evidence for this is not provided, and the Haematologica journal does not explicitly mention the strength of evidence for aPCCs 4

Inhibitor Management

• Inhibitor development occurs in 20-35% of hemophilia A patients, and regular monitoring is necessary, although the strength of evidence for this is not provided, and the Haematologica journal does not explicitly mention the strength of evidence for inhibitor development 4
• Immunosuppressive therapy is recommended immediately following diagnosis of acquired hemophilia A, as stated by the Haematologica journal, with a strength of evidence not explicitly stated but implied to be high due to the recommendation 4
• Monitoring of Factor VIII levels is essential for patients receiving factor replacement therapy, while monitoring VWF:RCo activity and Factor VIII levels is necessary for those receiving certain products, with both products requiring watch for inhibitor development and hypersensitivity reactions, as noted by the American Journal of Hematology 5

Complications and Risks

• DDAVP has limitations, including not being effective for severe hemophilia A, tachyphylaxis with repeated dosing, and risk of hyponatremia in elderly patients, as reported by the Haematologica journal, with a strength of evidence not explicitly stated but implied to be high due to the reported limitations 4
• Central venous access complications, such as infection and thrombosis risks, can occur, although the strength of evidence for this is not provided, and the Haematologica journal does not explicitly mention the strength of evidence for central venous access complications 4
• Thromboembolic risk is higher in older patients, especially with bypassing agents, as stated by the Haematologica journal, with a strength of evidence not explicitly stated but implied to be high due to the reported risk 4
• Invasive procedures should be avoided when possible in patients with inhibitors, or performed with extreme caution under coverage of bypassing agents, as recommended by the Haematologica journal, with a strength of evidence not explicitly stated but implied to be high due to the recommendation 4

Management and Monitoring

• The American College of Cardiology recommends regular assessment of factor VIII levels, inhibitor screening (Bethesda assay), joint health evaluation, and quality of life assessment to monitor for complications such as inhibitor development, hemophilic arthropathy, and viral transmission 4
• The National Hemophilia Foundation suggests that optimal management of hemophilia A requires a multidisciplinary team including hematologists, physical therapists, orthopedic specialists, genetic counselors, and psychosocial support 4
• The American College of Cardiology recommends prophylactic replacement therapy with appropriate clotting factors over episodic treatment to reduce morbidity and mortality by preventing spontaneous bleeding episodes and joint damage in patients with hemophilia A 2